RxDoctor Payments Data

Tricia Miller, MD

Pediatrics · Holland, MINPI 1033226618

Payments from drug & device makers

$2,753in general payments, 2019–2025

Across 167 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$534
  • Supernus Pharmaceuticals, Inc.$312
  • GSK$306
  • Novo Nordisk$291
  • AstraZeneca$271
  • Merck$152
  • plus $887 from 26 others

What the payments were for

  • Food & beverage$2,57694%
  • Education$1766%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,753 in reported general payments places this provider in the 90th percentile of 1,473 pediatrics providers in Michigan.

See all pediatrics providers in Michigan

Medicare billing

Part B allowed, 2024
$11,068
Medicare patients
49
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$74,015
MounjaroTirzepatide58$58,660
OzempicSemaglutide35$32,542
TrulicityDulaglutide36$32,258
FarxigaDapagliflozin Propanediol28$28,582
JardianceEmpagliflozin23$23,588
XareltoRivaroxaban16$22,633
Soliqua 100-33Insulin Glargine/Lixisenatide22$19,350
MyrbetriqMirabegron19$17,871
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$14,293
ArexvyRsvpref3 Antigen/As01e/Pf31$9,868
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$6,904
LinzessLinaclotide11$6,673
Atorvastatin Calcium325$6,180
Levothyroxine Sodium266$5,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$99$90,91894 claims
PfizerEliquis$149$74,01589 claims
Novo NordiskOzempic$291$32,54235 claims
AstraZenecaFarxiga$271$28,58228 claims
Boehringer IngelheimJardiance, Combivent Respimat$71$28,57135 claims
Johnson & JohnsonXarelto$27$22,63316 claims
GSKArexvy, Anoro Ellipta, Shingrix$306$21,75668 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$25$19,35022 claims
AbbVieLinzess$534$6,67311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,473 pediatrics providers in Michigan.

Other pediatrics in Holland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →